Advertisement

Topics

Navamedic ASA: Q3 2017 results

01:59 EST 10 Nov 2017 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
  Oslo, November 10, 2017 - Navamedic ASA (OSE: NAVA), reported revenues of NOK 44.9 million in the third quarter of 2017, down from NOK 65.2 million in the same period in 2016, following the planned discontinuation of the Aspen a...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Navamedic ASA: Q3 2017 results "

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.